Currently out of the existing stock ratings of Daina Graybosch, 106 are a BUY (77.94%), 27 are a HOLD (19.85%), 3 are a SELL (2.21%).

Daina Graybosch

Work Performance Price Targets & Ratings Chart

Analyst Daina Graybosch, currently employed at LEERINK, carries an average stock price target met ratio of 28.12% that have a potential upside of 39.3% achieved within 176 days.

Daina Graybosch’s has documented 260 price targets and ratings displayed on 26 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on SMMT, Summit Therapeutics PLC at 12-Aug-2026.

Wall Street Analyst Daina Graybosch

Analyst best performing recommendations are on SBTX (SILVERBACK THERAPEUTICS ).
The best stock recommendation documented was for SBTX (SILVERBACK THERAPEUTICS ) at 12/29/2020. The price target of $40 was fulfilled within 1 day with a profit of $3 (8.11%) receiving and performance score of 81.08.

Average potential price target upside

of $29.18 (41%) on MRK (MERCK MPANY).
of $24.5 (67.89%) on AFMD (AFFIMED NV).
of $22.21 (158.3%) on ACLX (ARCELLX).

ACLX Arcellx BNTX BioNTech SE FATE Fate Therapeutics MRK Merck mpany SBTX Silverback Therapeutics AFMD Affimed NV CGEN Compugen IPHA Innate Pharma IPSC Century Therapeutics ITOS Iteos Therapeutics MOLN Molecular Partners AG ADR NKTR Nektar Therapeutics BOLT Bolt Biotherapeutics FSTX FStar Therapeutics HOWL Werewolf Therapeutics LVTX LAVA Therapeutics NV TSVT 2Seventy Bio RCUS Arcus Biosciences KDNY Chinook Therapeutics ADRO Aduro Biotech ADAG Adagene GNCA Genocea Biosciences IT Gartner SB Safe Bulkers SMMT Summit Therapeutics PLC XLO Xilio Development

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Kelsey Goodwin (PIPER SANDLER)